← Leaderboards
Jing Chen
Boston Children'S Hospital
$8,468,363
Attributed
$8,468,363
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1M · FY2015–25$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,468,363 · 3
By mechanism
R01$8,468,363 · 3
Top collaborators
No co-investigators on record.
Most similar at Boston Children'S Hospital
Same institution · by research overlap
- Christina Marie Jacobsen$3,719,047
Others in their field
Top investigators on “Link”
- Robert B Gagosian · Consortium For Ocean Leadership, Inc$232,495,072
- David R. Weir · University Of Michigan At Ann Arbor$206,261,870
- Clare E Reimers · Gordon Research Conferences$205,233,456
- Demian A Bailey · Oregon State University$205,233,456
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$143,577,666
- Greg Ulses · Consortium For Ocean Leadership, Inc$140,113,248
Research focus
LinkLigandsMouse ModelPathway InteractionsGenetic TranscriptionDesignBlindnessEye DiseasesRetinaTranscriptional RegulationMediatingPublic Health RelevanceGenesAffectLeadFamilyFundusIn VitroPathologicComplementIn VivoCell Culture TechniquesAgonistAge Related Macular Degeneration
Grant awards (18)
RORalpha mediates chronic subretinal inflammation associated with AMD$507,705
R01 · FY2025 · EY · contact PI
RORalpha mediates chronic subretinal inflammation associated with AMD$507,705
R01 · FY2024 · EY · contact PI
Regulation of RPE degeneration by REV-ERBalpha$533,218
R01 · FY2023 · EY · contact PI
RORalpha mediates chronic subretinal inflammation associated with AMD$507,705
R01 · FY2023 · EY · contact PI
Regulation of RPE degeneration by REV-ERBalpha$517,221
R01 · FY2022 · EY · contact PI
RORalpha mediates chronic subretinal inflammation associated with AMD$507,705
R01 · FY2022 · EY · contact PI
Regulation of RPE degeneration by REV-ERBalpha$517,220
R01 · FY2021 · EY · contact PI
Wnt signaling-mediated control of blood-retinal barrier$429,225
R01 · FY2021 · EY · contact PI
Regulation of RPE degeneration by REV-ERBalpha$533,218
R01 · FY2020 · EY · contact PI
Wnt signaling-mediated control of blood-retinal barrier$442,500
R01 · FY2020 · EY · contact PI
Wnt signaling-mediated control of blood-retinal barrier$442,500
R01 · FY2019 · EY · contact PI
Nuclear receptor mediated ocular neovascularization$442,500
R01 · FY2019 · EY · contact PI
Wnt signaling-mediated control of blood-retinal barrier$442,500
R01 · FY2018 · EY · contact PI
Nuclear receptor mediated ocular neovascularization$442,500
R01 · FY2018 · EY · contact PI
Wnt signaling-mediated control of blood-retinal barrier$442,500
R01 · FY2017 · EY · contact PI
Nuclear receptor mediated ocular neovascularization$438,650
R01 · FY2017 · EY · contact PI
Nuclear receptor mediated ocular neovascularization$438,650
R01 · FY2016 · EY · contact PI
Nuclear receptor mediated ocular neovascularization$375,141
R01 · FY2015 · EY · contact PI